Vox sanguinis · 2026
Rapid anti-HPA-1a antibody quantification with a Luminex bead-based assay: A method evaluation.
СтатьяОценочное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Asplund Högelin Klara, Deschmann Emöke, Höglund Petter, Wikman Agneta
Аннотация
BACKGROUND AND OBJECTIVES: High concentration of human platelet antigen-1a (HPA-1a) antibodies is reported to be associated with severe foetal and neonatal alloimmune thrombocytopaenia (FNAIT). The gold standard for quantification of anti-HPA-1a antibodies is the monoclonal antibody immobilization of platelet antigen (MAIPA) assay, which is a laborious method performed in only a few reference laboratories. The aim of this study was to evaluate the performance of the commercially available bead-based Luminex assay PakLx (Immucor) for quantitative measurement of anti-HPA-1a antibodies.
MATERIALS AND METHODS: We analysed anti-HPA-1a antibody levels in plasma samples from 42 HPA-1a-negative women who had given birth to a child with thrombocytopaenia. Quantification of antibodies was performed with two different techniques: MAIPA analysed by spectrophotometry with results expressed in international units (IU)/mL, and PakLx analysed in the Luminex assay with results expressed as the mean fluorescence intensity (MFI).
RESULTS: In the comparison of the two methods' ability to stratify a result as either positive or negative, PakLx demonstrated 97.6% agreement with the MAIPA assay, with positive and negative predictive values of 96.7% and 100%, respectively. The correlation of the MFI values from PakLx with IU/mL in MAIPA assay was high, with a correlation coefficient (R2) of 0.92. MFI values were converted into semi-quantitative results: high, intermediate and low levels of anti-HPA-1a.
CONCLUSION: PakLx shows high agreement with the MAIPA assay and allows fast laboratory turnaround time for the determination of anti-HPA-1a antibody levels. The result may be of predictive value in clinical assessments.
MATERIALS AND METHODS: We analysed anti-HPA-1a antibody levels in plasma samples from 42 HPA-1a-negative women who had given birth to a child with thrombocytopaenia. Quantification of antibodies was performed with two different techniques: MAIPA analysed by spectrophotometry with results expressed in international units (IU)/mL, and PakLx analysed in the Luminex assay with results expressed as the mean fluorescence intensity (MFI).
RESULTS: In the comparison of the two methods' ability to stratify a result as either positive or negative, PakLx demonstrated 97.6% agreement with the MAIPA assay, with positive and negative predictive values of 96.7% and 100%, respectively. The correlation of the MFI values from PakLx with IU/mL in MAIPA assay was high, with a correlation coefficient (R2) of 0.92. MFI values were converted into semi-quantitative results: high, intermediate and low levels of anti-HPA-1a.
CONCLUSION: PakLx shows high agreement with the MAIPA assay and allows fast laboratory turnaround time for the determination of anti-HPA-1a antibody levels. The result may be of predictive value in clinical assessments.